News | Patient Monitors | September 09, 2015

Simple Test Predicts Obstructive Sleep Apnea in Hospitalized Heart Failure Patients

Overnight pulse-oximetry correlates with outpatient polysomnography

sleep apnea, pulse oximetery, congestive heart failure, CHF, pulse-oximetry, Thomas Jefferson University

September 9, 2015 — Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF). The results were published in the Journal of American College of Cardiology: Heart Failure.

“Since traditional screenings are not always effective in patients with congestive heart failure, additional tools are needed,” said lead author Sunil Sharma, M.D., FAASM, associate professor of pulmonary medicine in the Sidney Kimmel Medical College at Thomas Jefferson University. “Our team was able to validate a screening strategy that can be instituted during hospitalization and effectively detect sleep disordered breathing among patients with congestive heart failure.”

This study adds to a growing body of research suggesting a connection between sleep disordered breathing and heart failure. “While an estimated 70 percent of patients with congestive heart failure have underlying sleep disordered breathing, only a minority, roughly 2 percent, are diagnosed and treated. Yet early recognition and treatment of this disorder in patients with congestive heart failure has been shown to improve ejection fraction, acute heart failure and may even reduce readmissions and mortality,” Sharma continued.

Consecutive patients admitted for congestive heart failure at Thomas Jefferson University Hospital were screened by respiratory therapists using the STOP-BANG Questionnaire (Snoring, Tiredness during daytime, Observed apnea, high blood Pressure – Body mass index greater than 35, Age greater than 50 years, Neck circumference greater than 40 centimeters and Male gender).

If the patient screened positive, they received a formal sleep consult during their hospital stay and underwent high-resolution pulse-oximetry testing, which assessed the patient’s oxygen desaturation index (ODI). This low-cost device measures how much oxygen is in a patient’s blood. Researchers hypothesized that dips in oxygen levels throughout the night were a sign of obstructive sleep apnea.

Patients with a high ODI were recommended to undergo overnight polysomnography as an outpatient. Of those who followed up with the recommended polysomnography (n=68), 94 percent (n=64) were diagnosed with sleep disordered breathing.

“Patients with congestive heart failure do not always present with traditional symptoms of sleep apnea, like daytime sleepiness and heavy snoring,” said Paul J. Mather, M.D., FACC, FACP, Lubert Family Professor of Cardiology in the Sidney Kimmel Medical College at Thomas Jefferson University and director of the Advanced Heart Failure and Cardiac Transplant Center at the Jefferson Heart Institute. “This study presents cardiologists with a cost-effective clinical pathway to detect sleep disordered breathing while these patients are hospitalized.”

“Our team’s research showed that overnight pulse-oximetry, a simple low cost device used in the hospital setting, correlates well with the gold-standard polysomnography,” said David J. Whellan, M.D., MHS, FACC, FAHA, the James C. Wilson Professor of Medicine in the Sidney Kimmel Medical College at Thomas Jefferson University and senior author on the study. “Future research is need to see if early screening and intervention of sleep disorder breathing, specifically obstructive sleep apnea, can reduce readmissions, morbidity and mortality in patients with congestive heart failure.”

For more information: www.jefferson.edu

Related Content

American Heart Association Introduces New Post-acute Care Heart Failure Certification
News | Heart Failure | July 03, 2019
The new Post-Acute Care Heart Failure Certification offered from the American Heart Association (AHA) provides...
Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
Overlay Init